Safety – Page 4 – Talk Bio

Actionable Insights Powered by AI

Reviva’s Brilaroxazine Demonstrates Efficacy and Safety in Long-Term Schizophrenia Treatment

8 months ago talkbio0Tagged Ability to perform cognitive activity, Antipsychotic Agents, Brilaroxazine, Effectiveness, Long-term, Negative, Safety, Schizophrenia, Symptoms aspect

Brilaroxazine, Schizophrenia treatment, Antipsychotic medication, Efficacy and safety, Long-term treatment, Negative symptoms, Cognitive functioning

FDA Halts Pediatric RSV Vaccine Trials Due to Safety Concerns

8 months ago talkbio0Tagged concerns, pediatric trials, Respiratory syncytial virus, Risk, Safety, United States Food and Drug Administration, Vaccines, VAERD

RSV vaccines, pediatric trials, safety concerns, FDA hold, VAERD risk

Keros Therapeutics Faces Major Setback as PAH Trial Dosing Suspended Over Safety Concerns

8 months ago talkbio0Tagged concerns, dosing, KER-012, PAH, Phase II TROPOS trial, Pulmonary arterial hypertension, Safety, Suspensions

Keros Therapeutics, PAH trial, dosing suspension, safety concerns, pulmonary arterial hypertension, cibotercept (KER-012), Phase II TROPOS trial

SIGA’s TPOXX Fails to Demonstrate Efficacy in Treating Mild to Moderate Mpox Cases: STOMP Study Results

8 months ago talkbio0Tagged 3-(2-methoxyphenyl)-5-methoxy-1,3,4-oxadiazol-2(3H)-one, antiviral treatment, Clinical Research, Effectiveness, Safety, Secretory Immunoglobulin A, STOMP, Technology, tecovirimat, Tpoxx

SIGA Technologies, TPOXX, Tecovirimat, Mpox, STOMP Study, Antiviral Treatment, Efficacy, Safety Profile

Moderna’s RSV Vaccines Face Safety Concerns Over Severe Infections in Infants

8 months ago talkbio0Tagged Advisory Committees, concerns, Infant, Moderna, Respiratory syncytial virus, RNA, Messenger, Safety, United States Food and Drug Administration, Vaccines

Moderna, RSV vaccines, safety concerns, severe infections, infants, mRNA vaccines, FDA, advisory committee

Advancements in BTK Inhibitors for Chronic Lymphocytic Leukemia: A Comparative Analysis of AstraZeneca, Eli Lilly, and BeiGene Therapies

9 months ago talkbio0Tagged acalabrutinib, AstraZeneca, BeiGene, Bruton's Tyrosine Kinase Inhibitors [MoA], Chronic Lymphocytic Leukemia, CLL, Continuous therapy, Effectiveness, Eli, Eli Lilly, Fixed-Duration Therapy, ibrutinib, Nemtabrutinib, Pirtobrutinib, Safety, zanubrutinib

BTK inhibitors, Chronic Lymphocytic Leukemia (CLL), AstraZeneca, Eli Lilly, BeiGene, Acalabrutinib, Ibrutinib, Zanubrutinib, Pirtobrutinib, Nemtabrutinib, Fixed-duration therapy, Continuous therapy, Efficacy, Safety

BioAge Labs Discontinues Phase II Obesity Study Due to Safety Concerns, Stock Plummets

9 months ago talkbio0Tagged Azelaprag, BioAge Labs, concerns, crash, liver transaminitis, Obesity, Phase 2 Clinical Trials, Safety

BioAge Labs, azelaprag, obesity treatment, Phase II study, safety concerns, liver transaminitis, stock crash

ASH 2024: Anito-cel Demonstrates Enhanced Response Rate and Consistent Safety in Phase II Update for Relapsed/Refractory Multiple Myeloma

9 months ago talkbio0Tagged 2024, anito-cel, Arcellx, Asymmetric Septal Hypertrophy, Phase II Update, Profiling (action), Rating (action), relapsed/refractory multiple myeloma, Response process, Safety

ASH 2024, Anito-cel, Arcellx, Relapsed/Refractory Multiple Myeloma, Phase II Update, Response Rate, Safety Profile

Novartis Reveals Sustained Efficacy and Safety of Fabhalta in Patients Switching from Anti-C5 Therapies for Paroxysmal Nocturnal Hemoglobinuria (PNH)

9 months ago talkbio0Tagged anti-C5, Avoidance, Blood Transfusion, Effectiveness, Fabhalta, Hemoglobin improvement, Iptacopan, Paroxysmal, Paroxysmal nocturnal hemoglobinuria, PNH, Safety, Switching therapies

Fabhalta (iptacopan), Paroxysmal Nocturnal Hemoglobinuria (PNH), Anti-C5 therapies, Efficacy and safety, Switching therapies, Hemoglobin improvement, Transfusion avoidance

AstraZeneca Addresses Safety Concerns Over Andexxa, Discontinues Opioid Use Disorder Drug

9 months ago talkbio0Tagged Andexxa, Anticoagulation Therapy, AstraZeneca, concerns, Opioid Use Disorder, Reversal, Safety, United States Food and Drug Administration

AstraZeneca, Andexxa, FDA, Safety Concerns, Anticoagulation Reversal, Opioid Use Disorder, AZD4041